Clinical Trials
52 trialsNCT03600350 2026-06-01
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT00458536 2026-05-19
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT03334305 2026-04-23
ACTION
University of Florida
Phase 1 Terminated
NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00661622 2025-05-16
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Thomas Jefferson University
Phase 2 Completed
NCT02465268 2025-01-14
ATTAC-II
University of Florida
Phase 2 Completed
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03927222 2024-04-08
I-ATTAC
Duke University
Phase 2 Terminated
NCT02593123 2023-01-23
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Phase 2 Completed
NCT01700673 2022-10-18
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00070070 2022-10-12
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02703714 2022-01-25
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
Phase 2 Completed
NCT02009397 2021-11-22
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
University of Louisville
Phase 1/2 Completed
NCT03615404 2021-01-28
ATTAC-P
Duke University
Phase 1 Completed
NCT01341652 2021-01-20
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00562328 2020-04-08
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Completed
NCT02786719 2020-03-12
SPRING
Baylor College of Medicine
Phase NA Completed
NCT00514215 2020-03-05
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02100930 2020-02-28
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02451488 2020-02-10
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
Phase 4 Completed
NCT00488982 2019-11-20
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
University of California, San Francisco
Phase 2 Completed
NCT00254592 2019-02-28
Neoadjuvant Treatment of Breast Cancer
University of California, Irvine
Phase 2 Completed
NCT00363649 2018-11-13
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00257322 2018-10-31
Cellular Immune Augmentation in Colon and Rectal Cancer
University of California, Irvine
Phase 2 Completed
NCT00940342 2018-09-19
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00400517 2018-08-28
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00090870 2018-07-12
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT01174082 2018-06-01
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00256243 2018-03-02
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
University of California, Irvine
Phase 2 Completed
NCT00411086 2017-12-05
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00466960 2017-08-28
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
University of Washington
Phase 2 Completed
NCT00003199 2017-07-12
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT00791037 2017-05-25
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
University of Washington
Phase 1/2 Completed
NCT00157573 2017-05-08
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00429416 2016-11-29
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Thomas Jefferson University
Phase 1/2 Completed
NCT00548847 2016-10-26
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Emory University
Phase 2 Completed
NCT00381004 2016-01-14
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00665002 2015-02-27
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00673179 2014-09-10
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00669318 2014-07-01
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT01542684 2014-04-30
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00499343 2013-08-02
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00085423 2013-04-10
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00939510 2013-01-31
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00429104 2012-12-06
Herceptin and GM-CSF for Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00323557 2012-12-05
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00501644 2012-08-07
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
M.D. Anderson Cancer Center
Phase 2 Completed